Dr. Brown is an Associate Professor of Molecular Oncology in the Department of Clinical Sciences. He also serves on the Executive Committee of the Colorado School of Public Health as the Faculty Lead of the Global Health and Health Disparities Concentration. He has joint faculty appointments in the Epidemiology Section of the Colorado School of Public Health, the Cell and Molecular Biology Graduate Degree Program, the Department of Ethnic Studies and the University Honors Program. Dr. Brown is a University Honors Professor of Infectious Disease and Biotechnology and he is a Director in the University’s Institute for Learning and Teaching. His research interests include: molecular oncology; epigenetics; histone modifications; lysine methylation; enzyme inhibitor design; cultural and environmental factors of cancer; issues of health disparities; cultural history of infectious disease; engaging underrepresented students in the sciences; and engaging undergraduates in research.
PhD, University of Texas at Austin, 2007MS, Georgetown University, , 2002BS, Colorado State University, 1998
Good Clinical Practices
Good Laboratory Practices
Good Manufacturing Practices
BioPharmaceutical Quality Assurance
Rhee C., Edwards M., Dang C., Harris J., Brown M, Kim J. and Tucker, H. ARID3A
is Required for Mammalian Placenta Development. Developmental Biology. 2017, 422(2): 83-91.
Schmidt C, Geyer M, Bohrisch J, Jentzen V, Gorczyza A, Khalil K, Volkert M, Brown MA, Sel
S and Storsberg J. Functionalization Strategies for Antibodies: Lessons Learned. American Journal of Immunology. 2017, 13(2): 144-154.
Edwards M, Alshiraihi I, Schmidt C, Storsberg J, and Brown MA. Nitric Oxide Mediated
Chemosensitization: Gene Therapy Versus Exogenous Introduction of NO Donors. In Bonavida, B. (Ed.), Nitric Oxide in Chemosensitization. Elsevier: Amsterdam. 2017.
Schmidt C, Yokaichiya F, Margareth Kazuyo Doganguzel N, Dias Franco M, Cavalcanti LP,
Brown MA, Alkschbirs MI, Ribeiro de Araujo D, Kumpugdee-Vollrath M, Storsberg J. An Abraded Surface of Doxorubicin-Loaded Surfactant-Containing Drug Delivery Systems Effectively Reduces the Survival of Carcinoma Cells. Biomedicines. 2016, 4(3): 22-35.
Alshiraihi, I. M. A., Bennett, J., Hamrick, M., Good, M., Henderson, K., Sobolewski, C.,
Edwards, M. A., Brown, M. A. Targeting the NS5 Protein of Zika Virus. J Mult Eng Sci St. 2016. 2(12): 1237-1240.
Brown MA, Foreman K, Harriss J, Das C, Zhu L, Edwards M, Shaaban S, Tucker H. C-
Terminal Domain of SMYD3 Serves as a Unique HSP90-Regulated Motif in Oncogenesis. Oncotarget. 2015, 6(6): 4005-19.
Bowser G, Wilkins K, Gretzel U, Davis E and Brown MA. Developing Research Networks
to Enhance Cross-Mentoring and Representation of Women in Clinical and Experimental Oncology. J Clin Exp Oncology. 2015, (4:3): 1-3.
Jarrell D, Hamrick ME, Good M, Chopp A, and Brown MA. Navigating Commercial
Approval of Therapeutics. Int Cancer Sci Ther. 2015, 2(3): 178-180.
Whitesell M, Alnajar S, Bowser G, and Brown MA. Cultural and Environmental Factors of
Triple-Negative Breast Carcinomas. Cancer Research Journal. 2014, 2(2) 18-28.
Bowser G, Gretzel U, Davis EB and Brown MA. Educating the Future of Sustainability.
Sustainability. 2014, 6(2): 692-701.
Dr. Brown specializes in molecular oncology and epigenetic factors of embryological development. : Clinical interests: clinical management of colorectal, hepatocellular, and breast carcinomas. : Research interests: molecular oncology; histone modifications; small molecule drug development; epigenetic factors in cardiac morphogenesis and hematopoiesis; cultural and environmental factors of cancer; engaging underrepresented students in the sciences; and engaging undergraduates in research.